©The Author(s) 2022.
World J Clin Cases. Oct 26, 2022; 10(30): 10921-10930
Published online Oct 26, 2022. doi: 10.12998/wjcc.v10.i30.10921
Published online Oct 26, 2022. doi: 10.12998/wjcc.v10.i30.10921
Table 2 Medical treatment in patients with ulcerative colitis
| Medical therapy | Current users, n (%) | Former users, n (%) | Never used, n (%) |
| Mesalazine, n = 425 | 368 (86.6) | 46 (10.8) | 11 (2.6) |
| Corticosteroids | 41 (9.1) | 228 (51.7) | 173 (39.2) |
| Thiopurines | 40 (9) | 69 (15.6) | 333 (75.4) |
| Methotrexate | 5 (1.1) | 4 (1) | 432 (97.9) |
| Infliximab | 55 (12.4) | 22 (5.0) | 365 (82.6) |
| Adalimumab | 12 (2.7) | 6 (1.4) | 424 (95.9) |
| Golimumab | 5 (1.1) | 11 (2.5) | 426 (96.4) |
| Vedolizumab | 11 (2.5) | 1 (0.2) | 430 (97.3) |
- Citation: Magrì S, Demurtas M, Onidi MF, Picchio M, Elisei W, Marzo M, Miculan F, Manca R, Dore MP, Quarta Colosso BM, Cicu A, Cugia L, Carta M, Binaghi L, Usai P, Lai M, Chicco F, Fantini MC, Armuzzi A, Mocci G. Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study. World J Clin Cases 2022; 10(30): 10921-10930
- URL: https://www.wjgnet.com/2307-8960/full/v10/i30/10921.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i30.10921